


## Effect of gadolinium-based contrast agent on breast diffusion-tensor imaging

August 6 2020



Axial dynamic contrast-enhanced subtracted image (A) and directional diffusion coefficient  $\lambda 1$  parametric maps (B and C) overlaid on T1-weighted image of central slice with unenhanced (B) and contrast-enhanced (C) administration are shown. There is substantial contrast in  $\lambda 1$  map between normal tissue (purple, with  $\lambda 1$  ? 1.7 × 10-3 mm2/s) and cancer (green-yellow-blue,  $\lambda 1$  American Journal of Roentgenology (AJR)

An "Original Research" article published in ARRS' *American Journal of Roentgenology* (*AJR*) concluded that the accuracy of breast cancer diagnosis via diffusion-tensor imaging (DTI) was equivalent both before and after the administration of a gadolinium-based contrast agent (GBCA), despite a value change in DTI parameters.



"However," wrote first author Anabel M. Scaranelo of Princess Margaret Cancer Centre's breast imaging division in Toronto, "the limitations in standardization of contrast enhancement implies that unenhanced diffusion measurements should be preferred."

In this <u>pilot study</u>, 26 women (age range 37-69 years) scheduled for a diagnostic breast MRI with BI-RADS categories 0, 4, 5, or 6 on conventional breast imaging were twice scanned using the same DTI sequence before and immediately after the breast dynamic contrastenhanced MRI.

Using dedicated DTI software, quantitative image analysis yielded parametric DTI maps of each directional diffusion coefficient (DDC), mean diffusivity, and maximal anisotropy of the lesions and normal tissue. Using appropriate statistical tests, these color maps were evaluated and lesion DTI parameters were compared before and after GBCA <u>administration</u>.

Fifty-eight percent of the cohort had <u>cancer</u> (13 infiltrating ductal carcinoma, two <u>ductal carcinoma</u> in situ), and 42% had benign or normal results. All breast cancers were visually detected in the DDC  $\lambda 1$  maps before and after GBCA administration. Mean cancer size derived from  $\lambda 1$  maps before GBCA administration was 15.3 mm—not statistically significantly different from the size derived after GBCA administration.

After GBCA administration, the cancers exhibited statistically significantly lower DDCs, mean diffusivity, and b0 intensity (p

Compared with before dynamic contrast enhancement, Scaranelo and colleagues' results showed statistically significant reduction in the DDCs of breast cancers after dynamic contrast enhancement, "leading to equivalent or increased conspicuity of the cancer lesions in the visual assessment by the radiologist," they noted.



Acknowledging the accuracy of <u>breast cancer</u> detection using unenhanced or contrast-enhanced DTI datasets was not significantly different, Scaranelo added that since DTI parameters are intrinsic tissue characteristics, the use of DTI before dynamic contrast enhancement can be fully standardized.

Scaranelo et al. explained further: "The contrast-enhanced DTI parameters are less amenable to standardization because their values depend on the type and dose of contrast agent and on variations in the contrast agent dynamics among the various types of <a href="mailto:breast">breast</a> cancers."

Thus, due to the lack of standardization of <u>contrast</u>-enhanced DTI, the authors of this AJR article still preferred unenhanced diffusion measurements.

**More information:** Anabel M. Scaranelo et al, Effect of IV Administration of a Gadolinium-Based Contrast Agent on Breast Diffusion-Tensor Imaging, *American Journal of Roentgenology* (2020). DOI: 10.2214/AJR.19.22085

## Provided by American Roentgen Ray Society

Citation: Effect of gadolinium-based contrast agent on breast diffusion-tensor imaging (2020, August 6) retrieved 25 April 2024 from <a href="https://medicalxpress.com/news/2020-08-effect-gadolinium-based-contrast-agent-breast.html">https://medicalxpress.com/news/2020-08-effect-gadolinium-based-contrast-agent-breast.html</a>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.